The Food & Drug Administration last week revised its Evusheld fact sheet for health care providers, recommending repeat dosing every six months if patients need ongoing protection. The FDA said data and modeling suggest that antiviral activity against the currently circulating SARS-CoV-2 variants and subvariants may be retained for six months at drug concentrations achieved following an Evusheld dose of 300 mg of tixagevimab and 300 mg cilgavimab. The previous fact sheet did not provide a specific recommendation on the dosing interval. 

Related News Articles

Headline
In mid-December, hospitals will transition to reporting COVID-19 data via the Centers for Disease Control and Prevention’s National Healthcare Safety Network,…
Headline
The Food and Drug Administration yesterday advised people who get a negative result from an at-home COVID-19 antigen test to test themselves again after…
Headline
The Department of Health and Human Services yesterday released new guidance on ordering, reporting, payment and cost-sharing for the COVID-19 monoclonal…
Headline
The Centers for Disease Control and Prevention today released updated guidance to help people protect themselves and others if they are exposed to, sick or…
#HealthCareInnovation Thursday Blog
Situated in the heart of Westchester County and just outside of New York City, White Plains Hospital was among the first hospitals in New York to face the…
Headline
Hospital leaders from the AHA’s vaccine confidence initiative share tips for building COVID-19 vaccine confidence. “Getting more Americans vaccinated against…